Also known as Ranexa
Ranolazine, sold under the trade name Ranexa by Gilead Sciences (who acquired the developer, CV Therapeutics in 2009), is an antianginal medication. In India, it is sold under the name "Ranozex". On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina pectoris.Source: Wikipedia
Estimated Total Cost: $208.8 for an average of 28 days supply
Patients are most commonly prescribed ranolazine to treat coronary atherosclerosis, angina, heart failure, and hypercholesterolemia.